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Abstract
Background
The receptor for advanced glycation end products (RAGE) is involved in the pathogenesis
of diabetic complications, and soluble forms of the receptor (sRAGE) can counteract the
detrimental action of the full-length receptor by acting as decoy. Soluble RAGE is produced
by alternative splicing [endogenous secretory RAGE (esRAGE)] and/or by proteolytic cleav-
age of the membrane-bound receptor. We have investigated the role of A Disintegrin And
Metalloproteinase 10 (ADAM10) in the ectodomain shedding of RAGE.
Methods
Constitutive and insulin-induced shedding of RAGE in THP-1 macrophages by ADAM10
was evaluated using an ADAM10-specific metalloproteinase inhibitor. Serum ADAM10
level was measured in type 1 diabetes and control subjects, and the association with serum
soluble RAGE was determined. Serum total sRAGE and esRAGE were assayed by ELISA
and the difference between total sRAGE and esRAGE gave an estimated measure of solu-
ble RAGE formed by cleavage (cRAGE).
Results
RAGE shedding (constitutive and insulin-induced) was significantly reduced after inhibition
of ADAM10 in macrophages, and insulin stimulated ADAM10 expression and activity. Dia-
betic subjects have higher serum total sRAGE and esRAGE (p<0.01) than controls, and
serum ADAM10 was also increased (p<0.01). Serum ADAM10 correlated with serum
cRAGE in type 1 diabetes (r = 0.40, p<0.01) and in controls (r = 0.31. p<0.01) but no correla-
tions were seen with esRAGE. The association remained significant after adjusting for age,
gender, BMI, smoking status and HbA1c.
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Conclusion
Our data suggested that ADAM10 contributed to the shedding of RAGE. Serum ADAM10
level was increased in type 1 diabetes and was a significant determinant of circulating
cRAGE.
Introduction
Proteolytic ectodomain release is one of the key mechanisms for regulating the function of a
number of cell surface proteins. The process, also known as shedding, is mediated mainly by
the proteinase family A Disintegrin And Metalloproteases (ADAMs) which are type 1 trans-
membrane proteins [1]. Twelve members of the ADAM family display catalytic function and
mediate the proteolytic cleavage of cell surface integral membrane proteins within their juxta-
membrane region, releasing a soluble protein ectodomain into the extracellular space. It has
been estimated that up to 4% of the proteins on the cell surface undergo ectodomain shedding
and this process affects functionally diverse proteins [2]. Dysregulation of ectodomain shed-
ding is associated with a wide range of pathological conditions, including autoimmune and car-
diovascular diseases, neurodegeneration, infection, inflammation and cancer [3].
ADAM10 is one of the proteolytically active ADAMmembers and has been studied in par-
ticular due to its potential role in the pathogenesis of Alzheimer’s disease, since amyloid pre-
cursor protein is one of the substrates of ADAM10 [4,5]. The number of recognized ADAM10
substrates is increasing, confirming the central role of ADAM10 in many important biological
processes, such as cell migration and axonal navigation, cell adhesion and regulation of
immune reactions and control of apoptosis [6,7]. Recent studies using cell lines have suggested
that ADAM10 is also involved in the cleavage of the receptor for advanced glycation end prod-
ucts (RAGE), a multi-ligand member of immunoglobulin superfamily of transmembrane cell
surface molecule [8]. Activation of the RAGE axis has been implicated in the pathogenesis of
diabetic vascular complications [9,10]. Soluble forms of RAGE can potentially act as decoy for
RAGE ligands and have been used as treatment to block RAGE activation in diabetic animals
[9]. It has been suggested that soluble forms of RAGE (sRAGE) can be produced by cleavage of
cell surface receptor (cRAGE) or by alternative splicing of the RAGE gene [endogenous secre-
tory RAGE (esRAGE)] [11,12].
Stimulation of RAGE shedding might potentially have a therapeutic value but the regulation
of this process is poorly understood. The process of shedding of cell surface proteins can be
constitutive and/or inducible. Shedding can be activated by G-protein coupled receptors, pro-
tein kinase C, intracellular calcium levels, membrane lipid composition and other experimental
and natural stimuli [13]. Recent studies have suggested that shedding of RAGE can be induced
in vitro. Proteolytic cleavage of full-length RAGE can be stimulated by Ca2+-ionophore iono-
mycin, G protein-couples receptors and by pharmacological agents like statins [14–17]. We
have recently shown that insulin also increases the cleavage of full-length cell surface RAGE to
form sRAGE in THP-1 macrophages [18]. Although in vitro studies have suggested a role of
ADAM10 in shedding of RAGE [8], its clinical significance remains unclear and has not been
investigated. In the present study, we have further determined the effect of insulin on
ADAM10 expression and activity in vitro and evaluated whether there are changes in
ADAM10 level in type 1 diabetes and its role in determining levels of circulating soluble RAGE
isoforms.
sRAGE and ADAM10 in Type 1 Diabetes
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Methods
In vitro studies
A human monocytic leukemia cell line, THP-1 cells (ATCC, Manassa., VA) was grown in
RPMI 1640 medium containing 10% FBS at 37°C in 5% CO2. Cells were plated and differenti-
ated for 72 hours before being used in experiments. The cells were then incubated with or with-
out insulin in the presence or absence of the indicated metalloproteinase inhibitors for each
experiment. To determine the role of ADAM10 in constitutive and insulin-induced shedding
of RAGE, cell-surface receptors of THP-1 macrophages were biotinylated with sulpho-
NHS-LC biotin (Pierce, Rockford, IL, USA). Cells were incubated with or without insulin (10
mIU/mL) for 24 hours. Cell conditioned-media was then harvested and immunoprecipitated
with anti-biotin agarose (Sigma, St. Louis, MA), and analyzed by immunoblotting with anti-
RAGE monoclonal antibody or streptavidin-HRP antibody (STP-HRP) (Abcam, Cambridge,
UK). Experiments were repeated in the presence of GM6001 (20uM), a broad-spectrum hydro-
xamate metalloproteinase inhibitor; or GI254023X (20uM), an ADAM10-specific metallopro-
teinase inhibitor, (Calbiochem, San Diego, CA) to block the shedding of RAGE.
To further investigate the effect of insulin on ADAM10 protein expression and activity and
cleavage of RAGE, dose-dependent experiments were performed. THP-1 macrophages were
incubated with increasing concentrations of insulin in serum-free and PMA-free medium for
24 hours. ADAM10 protein expression was measured by Western blot and ADAM10 activity
in cell lysate was determined by a fluorimetric assay (SensoLyte 520 ADAM10 activity assay
kit, Fremont, CA). Cell conditioned-media was harvested for measurement of cRAGE. All
experiments were repeated 3–5 times. Experiments to determine the effect of insulin on
ADAM10 protein expression and shedding of RAGE were also repeated in human monocyte-
derived macrophages (MDMs). Peripheral blood mononuclear cells were first isolated from
healthy control subjects by density centrifugation using Ficoll (GE Healthcare Bio-Sciences,
Pittsburgh, PA). Purified monocytes (2x106cells/ml) were cultured in IMDM (Invitrogen,
Grand Island, NY) medium supplemented with penicillin-streptomycin and 20% (vol/vol)
autologous serum for 8 days to allow differentiation into monocyte-derived macrophages.
Clinical study
Patients with type 1 diabetes were recruited from the diabetes clinic at Queen Mary Hospital.
Patients with malignancy, connective tissue disease, previous history of cardiovascular disease,
liver dysfunction or renal impairment were excluded. Patients on statin therapy were also
excluded as statins have been shown to induce RAGE shedding [16,17]. Healthy control sub-
jects were recruited from the community and none of them had history of chronic illness and/
or was receiving regular medications. The study was approved by the Ethics Committee of the
University of Hong Kong, and written informed consent was obtained from all subjects. Fast-
ing blood samples were taken for the measurement of glucose, HbA1c, lipids, creatinine,
ADAM10, sRAGE and esRAGE.
Immunoprecipitation of serum ADAM10 protein using a rabbit anti-human polyclonal
antibody specific to ADAM10 (Millipore, CA) followed by Western blot analysis was first per-
formed to prove that ADAM10 was detectable in human serum. An in-house competitive
ELISA was then developed to measure serum level of ADAM10. 50ul of 50ng/ml synthetic pep-
tide of human ADAM10 (amino acids 732–748 near the C-terminus, Millipore, CA) was first
coated overnight at 4°C in 0.1M sodium bicarbonate, pH 9.6. Serum samples were one-fourth
diluted with 1% BSA/PBS prior to the assay. After blocking the ELISA with 5% BSA/PBS for 3
hours, 50ul of either above 1/4 diluted serum samples or series diluted antigen standards plus
sRAGE and ADAM10 in Type 1 Diabetes
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50ul of 1:50000 rabbit polyclonal anti-human ADAM10 antibody was added to wells for 3
hours incubation at room temperature. Post-secondary goat-anti-rabbit polyclonal HRP conju-
gated IgG (100ul, Sigma, St. Louis, MO) at 1:2000 dilution was added after 5 times of buffer
washes. After further washing steps, 100ul per well of 3,30,5,50-tetramentylbenzidine substrate
(TMB substrate kit; Pierce Rockford, IL) was added for 20mins followed with 50ul per well of
2M sulfuric acid (H2SO4) as stop solution. Absorbance reading was read within 30mins by an
ELISA reader at 450nm. The standard curve was linear between 80 and 250ng/ml by using
known concentrations of ADAM10 peptide as the standard to ADAM10 antibody. The average
recovery was 101%, and ranged from 84 to 109% accordingly. The intra- and inter-assay coeffi-
cients of variation (CV) of the competitive ELISA were 4.1% and 7.7%, respectively.
Serum sRAGE (Quantikine; R&D systems, Minneapolis, MN, USA) and esRAGE levels
(B-Bridge International Inc., CA, USA) were measured using commercially available ELISA
kits according to the manufacturer’s protocol. Measurements were performed in duplicate. The
intra- and interassay CV were 1.9% and 5.5% for sRAGE respectively and 3.7% and 5.4% for
esRAGE respectively. There is no assay that can specifically measure soluble forms of RAGE
formed by shedding. Hence, we have used the difference between total sRAGE and esRAGE as
an estimated measure of soluble forms of RAGE formed by cleavage (cRAGE). Plasma total
cholesterol, HDL cholesterol and triglycerides were determined enzymatically on an analyzer
(Hitachi 912; Roche Diagnostics). LDL cholesterol was calculated by the Friedewald equation
or measured directly if fasting triglyceride was greater than 4.5 mmol/L. HbA1c was measured
in whole blood using ion-exchange high-performance liquid chromatography with the Bio-
RAD Variant Haemoglobin Testing System (Bio-Rad Laboratories, Hercules, CA, USA). Esti-
mated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal
Disease (MDRD) Study equation.
Statistical Analyses
Data that were not normally distributed were logarithmically transformed before analyses were
made. Differences in continuous variables between diabetic patients and controls were deter-
mined by independent sample t-test. Pearson’s correlations were used to test the relationship
between variables and multiple linear regression model was used to assess the relationships
between soluble RAGE isoforms and various variables simultaneously.
Results
The role of ADAM10 in constitutive and insulin-stimulated shedding of RAGE in THP-1 mac-
rophages was first investigated in vitro and the results are shown in Fig 1A and 1B respectively.
Cell surface RAGE was biotinylated and the amount of biotinylated RAGE shedded into cell
conditioned media represented cRAGE formed by ectodomain cleavage of RAGE. The addition
of either GM6001 or G1254023X significantly reduced the amount of biotinylated RAGE in
cell-conditioned media (Fig 1A). The decrease in biotinylated RAGE in cell-conditioned media
was greater when the specific ADAM10 inhibitor G1254023X was used, suggesting that consti-
tutive shedding of RAGE was blocked by inhibiting ADAM10. In cells treated with insulin for
24 hours, insulin increased shedding of biotinylated RAGE into cell-conditioned media by at
least 1.5 fold and this process could also be blocked by inhibiting ADAM10 (Fig 1B).
To further investigate whether insulin increased shedding of RAGE by stimulating
ADAM10 expression and/or activity, THP-1 macrophages were incubated with increasing con-
centrations of insulin, and ADAM10 protein expression and activity in cell lysate was deter-
mined. Western blot analysis showed that insulin increased ADAM10 expression in a dose-
dependent manner (Fig 2A). This was paralleled by an increase in ADAM10 activity in the cell
sRAGE and ADAM10 in Type 1 Diabetes
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Fig 1. Effect of inhibition of ADAM10 on constitutive (A) and insulin-induced shedding of RAGE (B) in THP-1 macrophages.Cell surface receptors
were biotinylated and cell-conditioned media was immunoprecipitated with anti-biotin agarose, electrophoresed and immunobloted with anti-RAGE antibody
or streptavidin-HRP (STP-HRP) antibody. Biotinylated RAGE in cell-conditioned media (cRAGE) was significantly reduced by addition of GM6001 (*p<0.05)
and GI254023X (**p<0.01) vs control cells (A). Cells were incubated with insulin (10mIU/ml) for 24 h in the presence or absence of inhibitors and biotinylated
RAGE in cell-conditioned media was quantified. Data represent the mean ± SEM. #p< 0.01 vs insulin-treated cells (B).
doi:10.1371/journal.pone.0137330.g001
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lysate (Fig 2B) and shedding of cell surface RAGE into cell-conditioned media which can be
blocked by inhibiting ADAM10 (Fig 2C). Taken together, our data would suggest that insulin
increases shedding of RAGE by stimulating ADAM10 expression and activity. In addition, we
have shown that insulin stimulates ADAM10 expression and shedding of cell surface RAGE
not only in THP-1 macrophages but also in human monocyte-derived macrophages (S1 Fig).
Since our in vitro experiments suggest that ADAM10 may play a role in insulin-stimulated
RAGE shedding, we have measured serum ADAM10 in a group of type 1 diabetic patients and
healthy controls, and evaluated the relationship between ADAM10 and the various soluble
RAGE isoforms. The clinical characteristics of the subjects are shown in Table 1. All patients
were treated with multiple daily insulin injections or were on continuous subcutaneous insulin
infusion. The mean total daily dose was 46±16 units. Fourteen percent of the patients had
microvascular complications. As expected, patients with type 1 diabetes had higher fasting glu-
cose and HbA1c. They also had lower plasma triglyceride and higher plasma HDL than con-
trol. Serum ADAM10 level was significantly increased in type 1 diabetic patients compared to
Fig 2. Effect of insulin on ADAM10 protein expression (A) and activity (B) and shedding of RAGE (C) in THP-1 macrophages. THP-1 macrophages
were incubated with increasing concentrations of insulin (0 to 50 mIU/ml) or blank medium as control for 24 hours. ADAM10 protein in whole cell lysate was
then measured byWestern blot (A) and cellular ADAM10 activity was measured by fluorimetric assay (B). Data represent the mean ± SEM. *p<0.05,
**p<0.01 vs control. Cell-conditioned media was harvested for quantification of cRAGE and experiments were repeated with the addition of specific ADAM10
inhibitor (C). *p<0.05 vs control, ##p<0.01 vs corresponding insulin-treated cells.
doi:10.1371/journal.pone.0137330.g002
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controls (Table 1). There was no correlation between serum ADAM10 level and daily insulin
dosage or age, BMI or HbA1c in the diabetic patients. Levels of serum sRAGE, esRAGE and
cRAGE are also shown in Table 1. Patients with type 1 diabetes had higher levels of sRAGE,
esRAGE and cRAGE than controls (p<0.01).
Correlation analysis was performed to determine whether there was any relationship
between ADAM10 and the various isoforms of soluble RAGE. Serum ADAM10 correlated
with sRAGE in both diabetic patients (r = 0.30, p<0.01) and controls (r = 0.30, p<0.01).
Hence, ADAM10 was associated with the total amount of soluble forms of RAGE in the circu-
lation. Further analysis showed that ADAM10 only significantly correlated with cRAGE (Fig
3A and 3B) but not with esRAGE. Multiple linear regression analysis was performed to deter-
mine whether ADAM10 remained a significant independent determinant of serum cRAGE in
patients with type 1 diabetes after adjusting for age, gender, body mass index, smoking status
and HbA1c. Serum ADAM10 was an independent determinant of serum cRAGE in patients
with type 1 diabetes (p<0.01), and accounted for 21% of the variation in serum cRAGE. Fur-
ther adjusting for duration of diabetes and insulin dose did not change the results.
Table 1. Clinical characteristics and serum levels of ADAM 10 and soluble RAGE isoforms in controls
and type 1 diabetic patients.
Control Type 1 DM
Number of subjects 101 102
Sex (male/ female) 42/58 40/60
Age (years) 43.2±10.2 42.1±11.1
Duration of diabetes (years) - 17.4 ± 9.1
BMI (kg/m2) 24.2±3.4 23.1±3.5*
Waist circumference (cm) 81.3±9.9 76.3±12.4**
Smoker (%) 9.9% 9.8%
ACEI/ARB (%) - 25.5%
SBP (mmHg) 117.2±15.2 121.8±17.2*
DBP (mmHg) 75.5±11.1 74.5±10.0
FG (mmol/L) 5.2±0.6 9.7±4.3**
HbA1c (%) 5.4±0.4 8.3±1.4**
HbA1c (mmol/mol) 35.5±4.4 67.1±15.1**
Total cholesterol (mmol/L) 4.85±0.87 4.79±1.10
Triglycerides (mmol/L) 1.00 (0.75–1.30) 0.70 (0.60–0.90)*
LDL (mmol/L) 2.76±0.77 2.67±0.91
HDL (mmol/L) 1.31±0.37 1.73±0.49**
Creatinine (umol/L) 78.7±16.5 75.3±16.3
eGFR (ml/min/m2) 90.6±17.0 93.6±16.4
ADAM10 (ng/ml) 156 (112–278) 324 (179–433)**
sRAGE (pg/ml) 802 (532–1129) 1038 (749–1217)**
esRAGE (pg/ml) 285 (210–381) 367 (269–476)**
cRAGE (pg/ml) 484 (283–796) 594 (447–812)**
Values are mean ± SD, or median (interquartile range) or percentage.
*p<0.05
** p<0.01 vs controls.
doi:10.1371/journal.pone.0137330.t001
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Discussion
The ADAMs are a large, widely expressed, and developmentally regulated family of proteins
and ADAM-mediated shedding of integral membrane proteins is essential for a number of bio-
logical processes important for embryonic development and tissue homeostasis[1,2]. ADAM10
Fig 3. Correlation between ADAM10 and cRAGE in type 1 diabetes (A) and control (B).
doi:10.1371/journal.pone.0137330.g003
sRAGE and ADAM10 in Type 1 Diabetes
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and ADAM17 are the main sheddases responsible for ectodomain shedding and changes in the
expression levels of ADAM and their dysregulated proteolytic activity can have pathological
consequences. ADAM10 mediates the shedding of the extracellular domains of a wide range of
transmembrane proteins including cell adhesion molecules, cadherins and nectin-1, chemo-
kines, amyloid precursor protein (APP), ephrins and Notch receptors. Hence, ADAM10-me-
diated shedding of these key proteins plays a major role in the regulation of chemotaxis,
inflammation, cell-cell adhesion, and induction of apoptosis [4–6]. Our experiments have
shown that ADAM10 also plays an important role in both constitutional and insulin-stimu-
lated shedding of RAGE in macrophages. As a result, ADAM10 can potentially alter RAGE-
ligand interaction by cleaving the cell surface receptor and reduce RAGE activation and signal-
ing. Ectodomain shedding of RAGE may therefore be one of the mechanisms involved in the
feedback regulation to limit the toxic effects of RAGE-mediated signaling, and targeting
ADAM10-mediated shedding of RAGE might have therapeutic potential [3].
In addition, we have further demonstrated that insulin can increase ADAM10 expression
and activity. Our findings differed from that of Chen et al. who reported that insulin stimulated
ADAM10 proteolytic activity without any demonstrable changes in protein expression [19].
These differences might be partly due to the different experimental conditions used such as the
much shorter incubation time in their study. In the present study, we found that the effect of
insulin on ADAM10 protein expression was mainly observed at the higher concentrations of
insulin. These concentrations are similar to the supraphysiological concentration of insulin
seen in the systemic circulation in patients receiving exogenous insulin therapy. Moreover, we
have measured ADAM10 activity using a fluorimetric assay and insulin increased both
ADAM10 protein expression as well as activity. Insulin may therefore be involved in the regu-
lation of RAGE expression and the production of soluble RAGE. We have previously reported
that insulin up-regulates full-length RAGE and esRAGE expression in macrophages [18].
Taken together, this would suggest that insulin not only increases cell surface full-length RAGE
expression, it also enhances the ectodomain shedding of RAGE through its effect on ADAM10
expression/activity.
In keeping with our in vitro data, we have found that ADAM10 level was increased in
patients with type 1 diabetes compared to non-diabetic controls. To our knowledge, this is the
first clinical study investigating ADAM10 level in patients with type 1 diabetes. Whether the
increase in ADAM10 level is related to the effect of exogenous insulin therapy remains to be
determined. We did not find any association between serum ADAM10 level and insulin dosage
of our patients, but total daily insulin dosage is a poor surrogate of plasma insulin level. In
addition to having higher serum ADAM10 level, circulating concentrations of sRAGE,
esRAGE and cRAGE were also elevated in patients with type 1 diabetes. There was a significant
correlation between ADAM10 and cRAGE both in patients with type 1 diabetes and healthy
controls, whereas no association between ADAM10 and esRAGE was seen. This is consistent
with the way that cRAGE and esRAGE is produced. In the circulation, cRAGE is produced by
ectodomain shedding by ADAM10 whereas esRAGE is formed by alternative splicing [11,12].
ADAM10 was an independent determinant of serum cRAGE and our data would suggest that
the higher concentration of cRAGE in patients with type 1 diabetes might be partly due to the
increase in ADAM10. We speculate that if insulin (especially exogenous insulin) plays a role in
regulating the expression and shedding of RAGE, this might partly explains why total sRAGE
levels are increased in majority of the studies in type 1 diabetes (reviewed in [20]). Although it
has been suggested that soluble forms of RAGE may be used as biomarkers of diabetic vascular
complications, it is clear that circulating RAGE isoforms are influenced by many confounding
factors including pharmacological agents.
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Our study has several limitations. We have only examined the effect of insulin on RAGE
shedding by ADAM10 in THP-1 macrophages and we have not examined other cell types like
endothelial cells and smooth muscle cells. Our clinical study is a cross sectional study and we
cannot prove any causal relationship between ADAM10 and cRAGE, and we have measured
only ADAM10 protein level and not activity. In addition, we did not directly assay cRAGE.
The assay for sRAGE does not distinguish between the different soluble RAGE species and the
assay measures total sRAGEin the circulation. The assay for esRAGE is more specific as the
detection antibody in the assay for esRAGE is a rabbit esRAGE-specific polyclonal antibody
raised against the unique C-terminal 16-amino-acid peptide (amino acids 332 to 347) of
esRAGE. We have used the difference between total sRAGE and esRAGE as a measure of
cRAGE because antibodies and corresponding assays for detection of cRAGE are not available.
Generation of antibodies specific to cRAGE has so far not been successful. We cannot exclude
the possibility there are minor secreted soluble splice variants of RAGE other than esRAGE in
the circulation that will be included as cRAGE in our study. However, the contribution is likely
to be small. Hudson et al have shown that esRAGE is the main splice variant that is secreted
from cells. Most of the other soluble splice variants of RAGE are degraded at mRNA level
through nonsense-mediated mRNA-decay pathway and not secreted [12].
In conclusion, we have shown that ADAM10 is involved in constitutional and insulin-stim-
ulated ectodomain shedding of RAGE in vitro. Serum ADAM10 level is increased in type 1 dia-
betes and there is a significant association between ADAM10 and serum cRAGE level. Our
data therefore suggest that ADAM10 might be involved in the regulation of RAGE in diabetes.
Supporting Information
S1 Fig. Effect of insulin on ADAM10 protein expression (A) and shedding of RAGE (B) in
human monocyte-derived macrophages (MDMs).Human MDMs were incubated with
increasing concentrations of insulin (0 to 50 mIU/ml) or blank medium as control for 24
hours. ADAM10 protein in whole MDMs lysate (A) and shedding of RAGE in MDMs-condi-
tioned media (B) were then measured by Western blot. Data represent the mean ± SEM.
p<0.05 vs control.
(TIF)
Author Contributions
Conceived and designed the experiments: KCBT ACHL SWMS. Performed the experiments:
ACHL SWMS. Analyzed the data: KCBT ACHL SWMS JKYL. Contributed reagents/materials/
analysis tools: KCBT ACHL SWMS. Wrote the paper: KCBT ACHL DJB. Recruited subjects
and collected clinical data: JKYL YW.
References
1. Huovila AP, Turner AJ, Pelto-Huikko M, Kärkkäinen I, Ortiz RM. Shedding light on ADAMmetalloprotei-
nases. Trends Biochem Sci. 2005; 30:413–422. PMID: 15949939
2. Tousseyn T, Jorissen E, Reiss K, Hartmann D. Make stick and cut loose—disintegrin metalloproteases
in development and disease. Birth Defects Res C Embryo Today. 2006; 78:24–46. PMID: 16622847
3. Saftig P, Reiss K. The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets
with therapeutic potential? Eur J Cell Biol. 2011; 90: 527–535 doi: 10.1016/j.ejcb.2010.11.005 PMID:
21194787
4. Endres K, Fahrenholz F. The Role of the anti-amyloidogenic secretase ADAM10 in shedding the APP-
like proteins. Curr Alzheimer Res. 2012; 9: 157–164 PMID: 21605036
5. Vingtdeux V, Marambaud P. Identification and biology of α-secretase. J Neurochem. 2012; 120 Suppl
1: 34–45 doi: 10.1111/j.1471-4159.2011.07477.x PMID: 22121879
sRAGE and ADAM10 in Type 1 Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0137330 September 1, 2015 10 / 11
6. Pruessmeyer J, Ludwig A. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in
brain pathology, inflammation and cancer. Semin Cell Dev Biol. 2009; 20:164–174. doi: 10.1016/j.
semcdb.2008.09.005 PMID: 18951988
7. Dreymueller D, Pruessmeyer J, Groth E, Ludwig A. The role of ADAM-mediated shedding in vascular
biology. Eur J Cell Biol. 2012; 91: 472–485. doi: 10.1016/j.ejcb.2011.09.003 PMID: 22138087
8. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, et al. A soluble form of the receptor
for advanced glycation end products (RAGE) is produced by proteolytic cleavage of the membrane-
bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008; 22:
3716–3727. doi: 10.1096/fj.08-109033 PMID: 18603587
9. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA. RAGE biology, atherosclerosis and diabetes. Clin
Sci (Lond). 2011; 121: 43–55
10. Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mechanisms in the patho-
genesis of diabetes and its complications. Ann N Y Acad Sci. 2011; 1243: 88–102. doi: 10.1111/j.1749-
6632.2011.06320.x PMID: 22211895
11. Vazzana N, Santilli F, Cuccurullo C, Davi G. Soluble forms of RAGE in internal medicine. Intern Emerg
Med. 2009; 4: 389–401 doi: 10.1007/s11739-009-0300-1 PMID: 19727582
12. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, et al. Identification, classification, and
expression of RAGE gene splice variants. FASEB J. 2008; 22: 1572–1580. PMID: 18089847
13. Postina R. Activation of α-secretase cleavage. J Neurochem. 2012; 120 Suppl 1: 46–54. doi: 10.1111/j.
1471-4159.2011.07459.x PMID: 21883223
14. Galichet A, Weibel M, Heizmann CW. Calcium-regulated intramembrane proteolysis of the RAGE
receptor. Biochem Biophys Res Commun. 2008; 370: 1–5. doi: 10.1016/j.bbrc.2008.02.163 PMID:
18355449
15. Metz VV, Kojro E, Rat D, Postina R. Induction of RAGE shedding by activation of G protein-coupled
receptors. PLoS One. 2012; 7(7):e41823. doi: 10.1371/journal.pone.0041823 PMID: 22860017
16. Tam HL, Shiu SW, Wong Y, ChowWS, Betteridge DJ, Tan KC. Effects of atorvastatin on serum soluble
receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis. 2010; 209: 173–
177. doi: 10.1016/j.atherosclerosis.2009.08.031 PMID: 19733353
17. Quade-Lyssy P, Kanarek AM, Baiersdörfer M, Postina R, Kojro E. Statins stimulate the production of a
soluble form of the receptor for advanced glycation end products. J Lipid Res.2013; 54: 3052–3061.
doi: 10.1194/jlr.M038968 PMID: 23966666
18. Lam JK, Wang Y, Shiu SW, Wong Y, Betteridge DJ, Tan KC. Effect of insulin on the soluble receptor for
advanced glycation end products (RAGE). Diabet Med.2013; 30: 702–709. doi: 10.1111/dme.12166
PMID: 23432638
19. Chen CD, Podvin S, Gillespie E, Leeman SE, AbrahamCR. Insulin stimulates the cleavage and release
of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci U S A. 2007; 104:
19796–19801. PMID: 18056631
20. Kalea AZ, Schmidt AM, Hudson BI. RAGE: a novel biological and genetic marker for vascular disease.
Clin Sci (Lond). 2009; 116: 621–637.
sRAGE and ADAM10 in Type 1 Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0137330 September 1, 2015 11 / 11
